MAIA Biotechnology, Inc. MAIA 深 沪
已收盘 10-31 16:00:00 美东时间
1.24
-0.070
-5.34%
华盛通- 最 高1.345
- 今 开1.34
- 成交量 50.41万股
- 最 低 1.22
- 昨 收 1.31
- 总市值 3815.55万
- 52周最高 2.90
- 市盈率 静 --
- 换手率 1.64%
- 52周最低 1.22
- 委 比 16.32%
- 总股本 3077.06万
- 历史最高 9.64
- 量 比 0.86
- 振 幅 9.54%
- 历史最低 0.82
- 每 手 1
- 风险率 0.32%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多MAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
MAIA Biotechnology announced the enrollment of five patients from Taiwan and Turkey in the expansion phase of its THIO-101 Phase 2 clinical trial, which evaluates ateganosine in combination with immune checkpoint inhibitors for advanced NSCLC patients resistant to prior therapies. The trial is ongoing across multiple continents, allowing access to a larger patient population. Dr. Saadettin Kiliçkap highlighted the potential of ateganosine to addr...
10-27 14:45
MAIA Biotechnology Showcases Promising Cancer Trial Results
MAIA Biotechnology, Inc. ( ($MAIA) ) just unveiled an announcement. On October ...
10-23 21:47
MAIA Biotechnology Reports Efficacy Of Ateganosine In High-Risk Non-Small Cell Lung Cancer At ESMO 2025
Outstanding measure of efficacy relative to high-risk cancers with limited treatment options CHICAGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage
10-23 20:38
MAIA Biotechnology Details 30-Month Patient Survival in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
CHICAGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. recently highlighted at the ESMO Congress 2025 in Berlin the exceptional results of its Phase 2 and Phase 3 clinical trials of ateganosine in non-small cell lung cancer (NSCLC). The company reported a third-line NSCLC patient showing 30-month survival, an outstanding measure for high-risk cancers with limited treatment options. Ateganosine, a telomere-targeting agent, has demonst...
10-23 12:36
MAIA Biotechnology Announces Private Placement Agreement
The latest update is out from MAIA Biotechnology, Inc. ( ($MAIA) ). On October ...
10-14 21:28
MAIA Biotechnology announces $0.74M private placement
MAIA Biotechnology (NYSE:MAIA) announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 0.60M shares of common stock at a purchase price of $1.22 per share...
10-14 04:45
MAIA Biotechnology adopts crypto treasury strategy; shares up
MAIA Biotechnology (NYSE:MAIA) has launched a digital asset treasury strategy, with approval to allocate up to 90% of its liquid assets into top-tier cryptocurrencies. Initial approved assets include ...
10-07 21:05
Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion
USA News Group News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 7, 2025 /PRNewswire/ -- USA News Group News Commentary – Major pharmaceutical companies are unveilin...
10-07 21:00
MAIA Biotechnology Authorizes Up To 90% Of Liquid Assets In Bitcoin, Ethereum, And USD Coin For New Digital Treasury Strategy
MAIA's Board of Directors authorizes holdings of up to 90% of the Company's liquid assets in cryptocurrencies (BTC), Ethereum (ETH), and USD Coin (USDC)CHICAGO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc.
10-07 20:49
